Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00501579 · ClinicalTrials.gov registry record · Phase 3

Study of Difluprednate in the Treatment of Uveitis

A Phase 3 study of Uveitis, sponsored by Sirion Therapeutics.

Completed
Registry status
Phase 3
Development phase
1
Study location

NCT00501579: Completed Phase 3 study of Uveitis, sponsored by Sirion Therapeutics.

NCT00501579 is a Phase 3 study of Uveitis that has completed, run by Sirion Therapeutics. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00501579, a Phase 3 study of Uveitis, has completed, sponsored by Sirion Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
1
Study location

Study Summary

The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.

Conditions Studied

Interventions

  • DRUG Difluprednate
  • DRUG Prednisolone Acetate

Study Locations (1)

Indiana

  • John-Kenyon American Eye Institute - New Albany

Trial Details

FieldValue
Phase Phase 3
Sirion Therapeutics

8 total trials

What the finished NCT00501579 record still lists

NCT00501579 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Difluprednate is the first listed.

NCT00501579 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT00501579 about?

NCT00501579 is a clinical study titled "Study of Difluprednate in the Treatment of Uveitis". The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.

What is the current status of trial NCT00501579?

This trial is currently completed. It is a Phase 3 study.

What conditions does trial NCT00501579 study?

This clinical trial studies the following conditions: Uveitis.

What interventions are being tested in trial NCT00501579?

The interventions under investigation include: Difluprednate (DRUG), Prednisolone Acetate (DRUG).

Who is sponsoring clinical trial NCT00501579?

This trial is sponsored by Sirion Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00501579 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Source: ClinicalTrials.gov NCT00501579, the US trial registry maintained by the National Library of Medicine. NCT00501579 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.